Junqiang Q. Zhang

No 81 Meishan Road
Hefei, 230032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Journal: Future oncology (London, England)

Published: June 03, 2026

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Journal: Lancet (London, England)

Published: April 23, 2026

The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving Immunotherapy.

The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving Immunotherapy.

Journal: Cancer medicine

Published: October 12, 2025

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Journal: Lancet (London, England)

Published: July 23, 2025

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Journal: Signal transduction and targeted therapy

Published: March 20, 2025

The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.

The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.

Journal: Scientific reports

Published: November 06, 2024

Integrated stress response mediates HSP70 to inhibit testosterone synthesis in aging testicular Leydig cells.

Integrated stress response mediates HSP70 to inhibit testosterone synthesis in aging testicular Leydig cells.

Journal: Reproductive biology

Published: July 25, 2024

Atlas and source of the microplastics of male reproductive system in human and mice.

Atlas and source of the microplastics of male reproductive system in human and mice.

Journal: Environmental science and pollution research international

Published: November 08, 2023

Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts.

Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts.

Journal: iScience

Published: June 21, 2023

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.

Journal: Cancer medicine

Published: February 07, 2023

Exposure to acrylamide inhibits testosterone production in mice testes and Leydig cells by activating ERK1/2 phosphorylation.

Exposure to acrylamide inhibits testosterone production in mice testes and Leydig cells by activating ERK1/2 phosphorylation.

Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Published: August 08, 2022

Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma.

Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma.

Journal: Journal of oncology

Published: July 26, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026